Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no!
- PMID: 29748244
- DOI: 10.1183/13993003.00730-2018
Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no!
Conflict of interest statement
Conflict of interest: W.W. Busse reports personal fees (consultancy) from 3M, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi-Regeneron and Teva; personal fees (data safety monitoring board) from Boston Scientific and Genentech; personal fees (royalties) from Elsevier; personal fees (educational videos) from Medscape; and personal fees (joint oversight committee) from ICON, all outside the submitted work.
Comment on
-
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study.Eur Respir J. 2018 May 10;51(5):1702523. doi: 10.1183/13993003.02523-2017. Print 2018 May. Eur Respir J. 2018. PMID: 29545284 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources